临床前CDMO研发筛选相关化合物

CDMO是Contract Development and Manufacturing Organization的缩写，即合同定制研发生产组织。它是一种为制药企业及生物技术公司提供医药（特别是创新药）工艺研发及制备、工艺优化、放大生产、注册和验证批生产以及商业化生产等定制服务的机构. 在传统代工基础上增加了研发和工艺优化能力，是高技术壁垒的工艺研发能力与规模生产能力的深度结合. 1, 工艺开发与优化：创新性合成路线设计、工艺参数优化. 2, 中试放大：实验室工艺向规模化生产的转化 3, 注册批生产：支持客户新药申报的验证批生产. 4, 商业化生产：药品上市后的大规模生产供应. 全球医药CDMO行业保持较高景气度。根据弗若斯特沙利文预测：2026年全球CDMO市场规模：预计达1,189亿美元 2033年全球CDMO市场规模：预计达3,385亿美元. CDMO作为医药产业链专业化分工的产物，已经从单纯的CMO代工模式升级为"研发+生产"一体化的高附加值服务。当前，在多肽、ADC、CGT等新型药物赛道的驱动下，全球及中国CDMO市场保持高速增长。中国CDMO企业凭借完整的供应链体系、工程师红利和一体化服务能力，全球市占率有望持续提升，行业正从"成本优势"竞争迈向"体系优势"竞争的新阶段。
如有产品调研服务, 请致函联系我们

客户展示

临床前CDMO研发化合物筛选

CAS: 204255-11-8

Oseltamivir Phosphate

中文名称:磷酸奥司他韦
CAS号:204255-11-8
分子式: C16H28N2O4.H3PO4 分子量: 410.40
产品形式: Phosphate salt
研发状态: Not yet recruiting
研发用途: Severe Influenza
研究机构: Assistance Publique - Hôpitaux de Paris
研发日期: December 1 2022
研发阶段: Not Applicable
Oseltamivir Phosphate(Tamiflu) is a potent and selective inhibitor of the neuraminidase that is essential for replication of influenza A and B viruses, used to prevent influenza.

CAS: 204205-90-3

Indibulin

中文名称:2-(1-(4-氯苄基)-1H-吲哚-3-基)-2-氧代-N-(吡啶-4-基)乙酰胺
CAS号:204205-90-3
分子式: C22H16ClN3O2 分子量: 389.83
产品形式: free base
研发状态: Unknown status
研发用途: Metastatic Breast Cancer
研究机构: Alaunos Therapeutics; Memorial Sloan Kettering Cancer Center
研发日期: Mar-10
研发阶段: Phase 1 : Phase 2
Indibulin (ZIO 301, D 24851, Zybulin) is an orally applied inhibitor of tubulin assembly with potent anticancer activity. Indibulin induces mitotic arrest and apoptosis.

CAS: 204005-46-9

Semaxanib (SU5416)

中文名称:1,3-二氢-3-[(3,5-二甲基-1H-吡咯-2-基)亚甲基]-2H-吲哚-2-酮
CAS号:204005-46-9
分子式: C15H14N2O 分子量: 238.28
产品形式: free base
研发状态: Terminated
研发用途: Brain and Central Nervous System Tumors
研究机构: Pediatric Brain Tumor Consortium; National Cancer Institute (NCI)
研发日期: Aug-00
研发阶段: Phase 1
Semaxanib (SU5416, semaxinib) is a potent and selective VEGFR(Flk-1/KDR) inhibitor with IC50 of 1.23 μM, 20-fold more selective for VEGFR than PDGFRβ, lack of activity against EGFR, InsR and FGFR. Phase 3.

CAS: 203120-46-1

Laninamivir Octanoate

中文名称:辛酸拉尼米韦
CAS号:203120-46-1
分子式: C21H36N4O8 分子量: 472.53
产品形式: Free base
研发状态: Completed
研发用途: Asthma
研究机构: Biota Scientific Management Pty Ltd; Department of Health and Human Services; Vaxart
研发日期: Oct-13
研发阶段: Phase 1
Laninamivir octanoate (CS-8958, R-118958, Inavir, LANI), a prodrug of Laninamivir (R-125489), is a long-acting neuraminidase (NA) inhibitor with superior anti-influenza virus activity.

CAS: 2030-63-9

Clofazimine

中文名称:氯苯吩嗪
CAS号:2030-63-9
分子式: C27H22Cl2N4 分子量: 473.40
产品形式: free base
研发状态: Completed
研发用途: Nontuberculous Mycobacterial Diseases
研究机构: Radboud University Medical Center
研发日期: February 14 2022
研发阶段: Phase 2
Clofazimine (NSC-141046) is a rhimophenazine dye, originally developed for the treatment of tuberculosis, it has both antimicrobial and antiinflammatory activity, postulated mechanisms of action include intercalation of clofazimine with bacterial DNA and increasing levels of cellular phospholipase A2.

CAS: 202590-98-5

Birabresib (OTX015)

中文名称:比拉瑞塞
CAS号:202590-98-5
分子式: C25H22ClN5O2S 分子量: 491.99
产品形式: free base
研发状态: Terminated
研发用途: NUT Midline Carcinoma (NMC); Triple Negative Breast Cancer (TNBC); Non-small Cell Lung Cancer (NSCLC); Castration-resistant Prostate Cancer (CRPC)
研究机构: Merck Sharp & Dohme LLC
研发日期: May 4 2016
研发阶段: Phase 1
Birabresib (OTX015, MK 8628) is a potent BET bromodomain inhibitor with EC50 ranging from 10 to 19 nM for BRD2, BRD3, and BRD4 in cell-free assays. Birabresib inhibits the expression of Nuclear receptor binding SET domain protein 3 (NSD3) target genes.